Navigation Links
Silencer Validated siRNAs


Silencer Validated siRNAs are single siRNA duplexes that have been verified by real-time RT-PCR to reduce the expression of a number of important human genes. The cut-off for siRNA validation is a >70% reduction in target gene expression 48 hours post-transfection, though the average reduction in target gene expression in the inital set of validated siRNAs is greater than 90%. Every Silencer Validated siRNA strand is purified by HPLC, tested for purity by capillary electrophoresis or analytical HPLC, and verified for identity by MALDI-TOF mass spectometry. After annealing, the siRNAs are analyzed by nondenaturing gel or capillary electrophoresis to confirm that the strands are properly annealed. The result is the highest quality siRNA with a sequence verified to reduce gene expression.


Cenix and the Genome-Wide siRNA Library
The validated siRNAs described here are the first of what will be many new products stemming from Ambion's collaboration with Cenix BioScience. Cenix was founded in 1999 and pioneered the use of genome-wide dsRNA libraries by targeting all of the genes in the C. elegans and Drosophila genomes (1). Cenix was the first company to espouse the goal of developing siRNAs for the entire human genome. To achieve this goal, Cenix developed design parameters to create more efficacious siRNAs and high-throughput screening methods to enable the rapid validation of siRNA activity. The partnership of Cenix BioScience and Ambion will result in a continuous production of new validated siRNAs for the human genome and ensure that these siRNAs are produced with the highest quality standards for the entire research community.


Creating Rules for siRNA Design
On average, 50% of the siRNAs featuring the Tuschl design rules (3' UU overhangs, <50% G/C content; 2-4) provide at least 50% reduction in target gene expression. An early goal for Cenix was to improve the percentage of effective siRNAs by improving the design rules for siRNAs. To accomplish this, Cenix tested several hundred siRNAs targeting a number of endogenous human gene products that were expressed at detectable levels in several different cell lines. The effective and ineffective siRNAs were used to judge the impact of a number of physical characteristics on siRNA activity, including Tm, predicted RNA secondary structure, nucleotide position effects, nucleotide content of the 3' overhangs, siRNA length, and nucleotide distribution over the length of the siRNA. Those characteristics that correlated with siRNA effectiveness were incorporated into a design algorithm. The final step of designing the algorithm was a BLAST search to ensure that the siRNA was specific to the gene of interest.

The algorithm was then tested for its capacity to identify effective siRNAs. siRNAs targeting 60 human genes were designed, prepared, and tested across as many as four cell lines. Of the genes whose expression could be reduced without causing cell death, 89% of the designed siRNAs provided greater than 70% reduction in target gene expression (Figure 1).

The design algorithm is now being tested on hundreds of human genes. The first siRNA sequences validated during this collaborative study are being made available by Ambion and Cenix BioScience as part of the Silencer Validated siRNA product line. As the study progresses, many more additional sequences will be added to this line.

Figure 1. Overall Performance of siRNAs Targeting Sixty Genes. siRNAs targeting 60 human genes were designed using the algorithm developed by Cenix. The top siRNA candidate for each target was prepared and transfected. Forty eight hours post-transfection, target gene expression was quantified by real-time RT-PCR. Relative reduction in mRNA expression was measured against cells transfected with a negative control siRNA. Sample size was normalized by measuring GAPDH in the various samples using real-time PCR.


Characteristics of Silencer Validated siRNAs
The average reduction in target gene expression achieved with the inital 45 Silencer Validated siRNAs tested is greater than 90% as measured by real-time RT-PCR, indicating that the design algorithm used is not only able to identify effective siRNAs at a high rate, but is also able to identify highly effective siRNAs. To further characterize the initial set of validated siRNAs, the potencies of a handful of the siRNAs were measured after transfecting HeLa cells with siRNAs at five different concentrations, ranging from 1-100 nM. As seen in Figure 2, each of the siRNAs provided a similar level of mRNA knockdown in cells transfected with 10 nM, 30 nM, and 100 nM siRNA. This confirms the potency of the siRNAs designed using the algorithm developed by Cenix, as well as the quality of the synthesis and purification processes being employed by Ambion for the Silencer Validated siRNAs. The siRNAs targeting survivin, CDK2, and GAPDH were tested further by transfecting HepG2, SK-N-AS, and MCF7 cells with five different concentrations of the siRNAs. Even in these more difficult to transfect cells, the Silencer Validated siRNAs were effective when transfected at concentrations below 100 nM, though the data point to the fact that poor transfection efficiency can be overcome by using higher concentrations of siRNA (Figure 3).

Figure 2. Effectiveness of Silencer Validated siRNAs at Various Concentrations. The indicated siRNAs were mixed with siPORT Lipid (Ambion) and the resulting complexes were added to HeLa cells in 24 well plates at the final concentration of siRNA shown. Forty-eight hours after transfection, RNA from the treated cells was recovered using the RNAqueous-MAG Total RNA Isolation Kit (Ambion) and reverse transcribed using the RETROscript Kit (Ambion). Target cDNA levels were measured by real-time PCR using SYBR Green assays. The expression of the target genes in the transfected cells was compared to cells transfected with an equal concentration of the Silencer Negative Control #1. Input cDNA in the different samples was normalized using real-time data for 18S rRNA. The bar graphs represent an average of three data points.

Figure 3. siRNA Activity in Various Cell Types. HeLa, HepG2, MCF7, and SK-N-AS cells in 24 well plates were transfected with the indicated siRNAs at various concentrations. Forty-eight hours after transfection, RNA from the samples was isolated using the RNAqueous-MAG Total RNA Isolation Kit (Ambion) and target gene expression was measured by real-time RT-PCR using SYBR green assays. The expression of the target genes in the transfected cells was compared to cells transfected with an equal concentration of the Silencer Negative Control #1 (Ambion). Input cDNA in the different samples was normalized using real-time data for 18S rRNA. The bar graphs represent the average of two data points per siRNA concentration.


Advantages of Using Highly Effective siRNA Sequences
The use of highly effective siRNAs, such as those included in the Silencer Validated siRNA product line, has a number of advantages over using moderately active siRNAs:

* It's possible to transfect less siRNA than what is traditionally used (e.g., 100 nM) and still see the same effect. You can, therefore, perform more experiments with a given amount of siRNA.

* Because less siRNA is needed, experiments can be designed that use multiple siRNAs transfected into the same cell sample without causing cytotoxicity (e.g., toxicity is usually a problem when transfecting cells with greater than 200 nM siRNA).

* Most importantly, using sequences that have been verified to effectively induce gene silencing avoids the need to screen siRNAs, and thus saves time and money, allowing the researcher to focus on biological questions. An example of one type of experiment that is possible with the Silencer Validated siRNAs is described in "Using Validated siRNAs in Functional Genomics Assays". Of course, many other applications exist, including target validation studies and pathway analysis.

* A single, validated siRNA does not require experiments to determine which siRNA is the functional siRNA of a mixture and permits easy scale-up for subsequent experiments in animals.

The following list includes some of the genes to which our initial offering of Silencer Validated siRNAs will be targeted. This list is subject to change. We are adding new Silencer Validated siRNAs on a continual basis. For an up-to-date list and to view additional information including full gene name, accession number, and knockdown efficiency of each validated siRNA, see www.ambion.com/prod/validated:


AKT1 APC1 Cyclin D1 Cyclin E1 ELK-1 ERBB-2 GSK-3b PCNA PKR uPAR


SYBR is a registered trademark of MolecularProbes.

Ambion is a licensed supplier of siRNA.

Designs for the Silencer Validated siRNAs are owned by Cenix and licensed to Ambion.


back to top


'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. pSilencer 4.1-CMV: Versatile Vectors for Expression of siRNA, miRNA, and mRNA
2. Selecting siRNA Sequences to Incorporate into the pSilencer Vectors
3. Your Data: Use of pSilencer 1.0-U6 siRNA Expression Vector in the Analysis of Synaptotagmin Location and Function
4. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
5. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
6. Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit
7. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
8. Using Validated siRNAs in Functional Genomic Assays
9. Cenix-Designed siRNAs for 95% of Human and Mouse Genomes
10. Five Ways to Produce siRNAs
11. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Silencer Validated siRNAs

(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... , - Company Also Granted Expansion of Prophylaxis Therapy Label ... , EXTON, Pa., June 4 ViroPharma Incorporated (Nasdaq: ... Complete Response letter from the U.S. Food and Drug Administration ... Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute ...
... SYDNEY, June 3 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... had raised A$47 million through a placement to,Australian and ... company,s balance sheet as Pharmaxis moves toward,the European and ... , Pharmaxis will issue 20 ...
... 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 11:30 am ET on Wednesday, June 10, 2009 at ... held in New York City. , , The presentation ...
Cached Biology Technology:ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 2ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 3ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 4ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 5Pharmaxis Announces Placement of $47 Million and Share Purchase Plan 2Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 2
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
(Date:7/25/2014)... shows that the age girls reach puberty is influenced by ... which parent contributes the gene. This is the first ... after birth and details of this study were published today ... first period, known as menarche, is a marker for the ... the onset of menses varies between girls, is an inherited ...
(Date:7/25/2014)... Biometrics industry expands and becomes ... technology for online & commerce payments while seeking security ... GOOG ), LifeLock Inc. (NYSE: LOCK ... Inc. (NASDAQ: AAPL ) and Fortinet Inc. ... biometric authentication company focused on the growing m-commerce market, ...
Breaking Biology News(10 mins):New hope for powdery mildew resistant barley 2Could age of first period influence development of diseases in older women? 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... DIEGO Research by the Scripps Translational Science Institute (STSI) ... the chest for up to two weeks does a better ... Holter monitor, which is typically used for 24 hours and ... years. The findings, which were published and made publically ...
... pain reliever in Chinese medicine may be just what the ... key pain-relieving ingredient is a compound known as dehydrocorybulbine (DHCB) ... , a member of the poppy family, according to researchers ... Current Biology on January 2. "Our study reports ...
... cancer, heart disease and other diseases were not enough motivation ... wake-up call: New research published in the January 2014 issue ... smoking disrupts the circadian clock function in both the lungs ... leading to cognitive dysfunction, mood disorders, depression and anxiety. ...
Cached Biology News:Patch outperforms Holter for prolonged heart rhythm tracking 2Plant used in Chinese medicine fights chronic pain 2Want a good night's sleep in the New Year? Quit smoking 2
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: